Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Abstract:
A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, Personalized and Precision Medicine (PPM). In this context, the need for innovative heart disease treatments has become critical since the diseases remain the world’s biggest killer. The pace of innovation in Personalized & Precision Cardiology (PPC) is becoming fast, including:
(i) a success of trans-catheter aortic valve implantation for patients or persons-at-risk at lower levels of surgical risk, or procedures to ablate atrial fibrillation with high degrees of success, and other interventional procedures;
(ii) a global shift from treating disease and preventing the secondary recurrence of cardiovascular events to the primary and even primordial biomarker-driven targeted prevention of cardiovascular risk and the promotion of cardiovascular health;
(iii) the widespread advent of wearable and implantable technologies, allowing continuous monitoring of cardiovascular parameters;
(iv) nanotechnology and microfluidics, AI and related areas to become the most rapidly emerging areas of cardiovascular research and the most promising technologies for improving health care and health outcomes.
The above-mentioned ares being an integral part of PPM-related cardiac research is really an interdisciplinary field that results from the application of the innovative tools to medicine and has the potential to significantly improve some canonical treatments, prevention, prophylaxis and rehabilitation. Specifically, in the field of PPC, expected to have a great impact in the near future due to its multiple advantages, namely its versatility to adapt a drug to cohorts of patients and/or persons-at-risk.
In cardiovascular disease globally, PPM may result in much-needed innovation in the field and has the potential to eventually change the way we treat heart diseases altogether. So, PPC is thus poised to become the next great revolution in the daily practice, as well as in the maintenance of cardiovascular health and the prevention and cure of cardiovascular disease. PPM disrupts standard practice and draws from clinical testing, electronic health records, multi-OMICS profiling, big datasets, and novel analytical methods, to create a person-specific phenotype to identify an optimal intervention with minimal risk.
The promise of PPM and PPC is well understood but the newest tools will be needed for describing the cardiovascular health status of individuals and populations, including transdisciplinary 'OMICS' data, exposome-related datasets and social determinants of health, behaviors and motivations, patient-generated data, and the array of data in EMRs. Innovative cardiology and cardiac nanosurgery currently lead the way in PPC advancements, and health care under PPM-related armamentarium will become a more integrated, dynamic system, in which patients are becoming central stakeholders who contribute data and participate actively in shared decision-making. The proposal would ideally be suited for practitioners who already incorporate integrative approaches in their practice, as well as more traditional clinicians who want to learn more about PPM and PPC as a growing area.
The upgraded and new strategy includes developing an emotive brand, using more social media, and minimizing noise by reducing technical language. By leveraging the business expertise these companies have in creating relationships with consumers, we believe that our collaboration with them will help us accelerate innovation in PPM and PPC by allowing patients and thus the persons-at-risk to understand their treatment (canonical, preventive and rehabilitative ones) options deeper and better.
PPM will need to demonstrate that phenotype-based person-specific interventions are superior to the current standard of care and, ultimately, have a population effect by moving the mean on the disease spectrum towards Health. Education, Affordability, and Public Acceptance of the strategy all play key roles in its ultimate implementation. This is the reason for developing global scientific, clinical, social, and educational projects in the area of PPM-based and PPC-guided clinical cardiology to elicit the content of the new branch. In short, PPM will transform the way the physicians practice and will shake up the entire pharmaceutical value chain.
